Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy

Area of Science:

• Molecular Biology
• Cancer Biology
• Pharmacology

Background:

• The B-cell lymphoma-2 (Bcl-2) protein family regulates apoptosis, a critical process in cell death.
• Overexpression of anti-apoptotic Bcl-2 proteins is prevalent in various cancers, contributing to tumor cell survival and chemotherapy resistance.

Purpose of the Study:

• To review the role of Bcl-2 proteins in cancer and apoptosis.
• To summarize the current advancements in Bcl-2 inhibitors, including their structure-activity relationships (SARs).
• To explore the synergistic effects of Bcl-2 inhibitors with other anti-cancer agents and discuss dual-targeting strategies.

Main Methods:

• Literature review of scientific publications on Bcl-2 proteins, apoptosis, and cancer therapy.
• Analysis of structure-activity relationships (SARs) for Bcl-2 inhibitors.
• Discussion of synergistic interactions between Bcl-2 inhibitors and other therapeutic targets like HDAC and Mdm2 inhibitors.

Main Results:

• Bcl-2 inhibitors represent a key therapeutic strategy for overcoming cancer drug resistance.
• Synergistic effects are observed when Bcl-2 inhibitors are combined with agents targeting other pathways (e.g., HDAC inhibitors, Mdm2 inhibitors).
• Dual-targeting therapies show potential for enhanced anti-cancer efficacy compared to single-agent treatments.

Conclusions:

• Targeting anti-apoptotic Bcl-2 proteins is crucial for effective cancer treatment.
• Dual-targeting strategies combining Bcl-2 inhibitors with other agents offer a rational approach to enhance therapeutic outcomes and overcome drug resistance.